BioSpace News Archive

The research was directed by two of Antibe’s founders, Drs. Andre Buret and John Wallace.

EVIO Inc. (“EVIO” or the “Company”), (OTCQB: EVIO), a leading North American provider of cannabis testing and scientific research for the regulated cannabis industry, is excited to announce the launch of its EVIO Biosciences Division.

The Janssen Pharmaceutical Companiesof Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with XARELTO® (rivaroxaban) over a two-year period compared to those taking warfarin.

91 accepted abstracts at ASCO, including LYNPARZA® (olaparib) in prostate cancer and moxetumomab pasudotox in hairy cell leukemia

The addition of Cxbladder Monitor for bladder cancer surveillance has been shown to enable physicians to reduce the overall number of diagnostic tests being ordered, potentially reducing the total cost of monitoring and reducing complications related to unnecessary tests.

Treatment of agitation in the elderly in hospital and nursing home settings represents a rapid potential path to market for BNC210 No currently approved treatments and significant unmet medical need

Phase 3 iLLUMINATE trial met primary endpoint of progression-free survival (PFS) in patients with previously untreated CLL and Small Lymphocytic Lymphoma (SLL) compared to chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC) Full study results may support an IMBRUVICA based, chemotherapy-free combination treatment option for patients

Medical Plastics Leader Enhances Specialty Products Portfolio Through Acquisition of former Adam Spence Corporation

Pivotal bioVenture Partners China (Pivotal China), a member of Nan Fung Life Sciences (NLFS) announced today the closing of Pivotal bioVenture Partners China USD Fund I, raising $150 million to incubate and build Life Sciences companies in China.

Sproutly Inc. (“Sproutly” or the “Company”) is pleased to announce that it has entered into non-binding letters of intent (the “Letters of Intent”) to acquire: 1) Infusion Biosciences Canada Inc., a biotech company possessing the rights to Infusion Biosciences Inc.’s (“Infusion Biosciences”) APP Technology (defined below) for specific jurisdictions;